Investee Company – Amedis Pharmaceuticals (UK)
Investee Company Business Type – Drug Development Company
Type of Financing – Expansion
Equity Providers – Merlin Biosciences, Avlar BioVentures Fund, and TTP Venture Fund
Equity Leader (Individual) – George Freeman, Merlin Biosciences
Debt Providers – No debt provided
Debt Type – N/A
Debt Leader (Individual) – N/A
Equity Amount – £4 million (euro6.5 million)
Total Deal Value – £4 million (euro6.5 million)
Other Advisors – No advisors were used in the deal
Comments – The financing was led by Merlin Biosciences, who founded the company in 1999, through Professor William Bains and Professor John Caldwell. Merlin invested £2.5 million while Avlar and TTP provided £1.5 million between them.
Amedis Pharmaceuticals is a drug development company providing proprietary technologies and products for the improvement of the medicinal properties of drugs. The Company is looking to address the current developmental bottleneck facing the pharmaceutical industry, using a combination of innovative chemistry, biology and bioinformatics.
Peter Keen, managing director of Merlin said of the research Amedis is carrying out: “These technologies have the long term potential to identify new classes of therapeutics with substantial benefits for the pharmaceutical industry.”
Professor William Bains, Amedis’ chief scientific officer, said: “The pharmaceutical companies need to focus on their resources on those compounds, which are most likely to be a success. It is of paramount importance that they have the best information available to them, Amedis can now plan to provide some of that information.”